Authors: Faycal El Majdoub Moataz Elawady Christian Bührle Mustapha ElKhatib Mauritius Hoevels Harald Treuer RolfPeter Müller Volker Sturm Mohammad Maarouf
Publish Date: 2012/01/29
Volume: 154, Issue: 4, Pages: 599-604
Abstract
Between May 2001 and July 2009 78 patients mf = 2454 median age 568 years range 201–81 years with 87 intracranial meningiomas 78 WHO I seven WHO II two WHO III were treated with μMLCLINAC radiosurgery at our institution either as a primary or salvage treatment following one or more microsurgical procedures Fiftyeight of 87 tumors 667 were located in the skull base The remaining 29 meningiomas 333 were located in the convexity of the brain The median tumor volume was 48 ml range 02–183 ml The median tumor surface dose maximal dose and therapeutic isodose were 12 Gy 16 Gy and 75 respectivelyFor retrospective evaluation we included 70 patients 78 tumors with a minimum radiological followup of 24 months After a median followup of 797 months range 242–1091 months 24 patients 343 improved in their clinical status paresis of N abducens 18/48 facial paresis 4/8 and hemiparesis 2/9 41 patients remained stable 586 three patients had treatmentrelated temporary complaints 43 two patients developed vertigo and one had a leftsided hemihypesthesia All complaints recovered completely after steroid medication within 2 weeks Two patients 28 developed permanent trigeminal neuralgia Followup MR images showed a partial remission in 21 tumors 269 and a stable tumor size in 55 cases 705 Two patients with highgrade meningiomas showed a tumor progression one WHO II and one WHO III meningioma At the end of followup July 2010 the actuarial 5 and 9year progressionfree survival after radiosurgery were 98 and 96 respectively There was no treatmentrelated mortality
Keywords: